How much weight gain is typical with hypothyroidism?

Most patients gain 5 to 10 pounds (2 to 4.5 kg), though 10 to 20 percent gain more. Roughly half is fluid (myxedema) and half is fat. Weight gain correlates with severity and duration of thyroid deficiency.

Does thyroid medication cause immediate weight loss?

Levothyroxine restores basal metabolic rate within weeks. Fluid weight (2 to 5 kg) often drops quickly. Fat loss requires sustained caloric deficit; medication alone rarely produces significant fat loss without dietary changes.

Why do some hypothyroid patients not gain weight?

Individual variation in appetite suppression, NEAT compensation, genetic metabolic flexibility, and concurrent conditions (e.g., malabsorption, hyperadrenergic state) can offset the positive energy balance. Weight stability does not exclude hypothyroidism.

Can subclinical hypothyroidism cause weight gain?

Subclinical hypothyroidism (elevated TSH, normal free T4) may cause modest BMR reduction (5 to 10 percent) and mild fluid retention. Weight gain is usually minimal (1 to 3 kg) and less consistent than in overt disease.

Why Hypothyroidism Causes Weight Gain: Metabolic and Hormonal Mechanisms

Thyroid Hormone Regulation of Basal Metabolic Rate

Thyroid hormones thyroxine (T4) and triiodothyronine (T3) act as master regulators of basal metabolic rate (BMR) in nearly every tissue. They enter cells via specific transporters and bind nuclear thyroid hormone receptors, modulating gene transcription for proteins involved in mitochondrial oxidative phosphorylation, ion transport, and substrate cycling. When circulating T3 and T4 fall, the transcriptional drive for these energy-consuming processes diminishes, lowering the calories expended at rest.

In overt hypothyroidism, BMR can decrease by 15 to 30 percent compared with euthyroid states. This reduction is not uniform across organs; the liver, heart, skeletal muscle, and brown adipose tissue show the most pronounced declines in oxygen consumption. The brain and spleen are relatively spared. The net effect is a positive energy balance even when caloric intake remains unchanged, creating the conditions for gradual weight accumulation.

Importantly, the BMR drop precedes measurable weight gain. Patients often report stable eating habits while weight creeps upward over months, reflecting the cumulative impact of a few hundred fewer calories burned daily. Restoring euthyroidism with levothyroxine typically reverses the BMR deficit within weeks, though full weight normalization may require additional dietary adjustment.

Diagram showing thyroid hormone entering a cell, binding nuclear receptor, and activating mitochondrial genes

Lipid Metabolism and Adipose Tissue Dynamics

Thyroid hormones stimulate lipolysis in white adipose tissue by upregulating hormone-sensitive lipase and adipose triglyceride lipase, while simultaneously suppressing lipoprotein lipase activity that promotes fatty acid uptake. In hypothyroidism, this balance shifts toward fat storage: lipolysis slows, lipoprotein lipase activity rises, and circulating free fatty acids decrease. The result is enhanced triglyceride deposition in adipocytes, particularly in visceral depots.

Hepatic lipid handling also changes. Reduced thyroid signaling decreases expression of LDL receptors on hepatocytes, impairing LDL clearance and raising serum LDL cholesterol — a classic hallmark of hypothyroidism. Concurrently, hepatic de novo lipogenesis may increase due to altered insulin signaling and substrate availability. These changes promote both adipose expansion and atherogenic dyslipidemia.

Brown adipose tissue (BAT), a major site of adaptive thermogenesis, is highly thyroid-dependent. T3 induces uncoupling protein 1 (UCP1) expression, enabling non-shivering heat production. Hypothyroidism suppresses BAT activity, reducing energy dissipation as heat. This loss of thermogenic capacity further widens the gap between intake and expenditure, favoring weight gain even without hyperphagia.

Fluid Retention and Myxedematous Weight Gain

Not all weight gain in hypothyroidism reflects fat accumulation. A significant fraction, especially early in the disease, stems from interstitial fluid retention driven by glycosaminoglycan (GAG) deposition. Thyroid hormone deficiency reduces fibroblast degradation of hyaluronic acid and other GAGs, which are highly hydrophilic. These molecules accumulate in the dermis, skeletal muscle, and serous cavities, binding water and creating a non-pitting edema known as myxedema.

This fluid retention can add 2 to 5 kilograms of weight independent of caloric balance. It manifests as puffiness around the eyes, swollen hands and feet, thickened tongue, and a doughy skin texture. Unlike adipose gain, myxedematous weight responds rapidly to thyroid hormone replacement, often resolving within weeks as GAG turnover normalizes and diuresis occurs.

Clinically, distinguishing fluid-driven weight from fat-driven weight matters for management expectations. Patients who lose several kilograms quickly after starting levothyroxine are primarily shedding retained water, not adipose tissue. True fat loss requires sustained negative energy balance, which restored BMR facilitates but does not guarantee without dietary attention.

Clinical photo showing periorbital puffiness and non-pitting edema in a patient with hypothyroidism

Appetite Regulation and Central Energy Homeostasis

Thyroid hormones influence hypothalamic circuits that control hunger and satiety. T3 modulates the expression of neuropeptide Y (NPY), agouti-related peptide (AgRP), pro-opiomelanocortin (POMC), and cocaine- and amphetamine-regulated transcript (CART) in the arcuate nucleus. In hypothyroidism, orexigenic signals (NPY/AgRP) may increase while anorexigenic signals (POMC/CART) decrease, potentially stimulating appetite.

However, clinical studies show inconsistent hyperphagia in hypothyroid patients. Many report unchanged or even reduced appetite, possibly due to comorbid depression, slowed gastric emptying, or altered gut hormone secretion (ghrelin, leptin, peptide YY). Leptin levels often rise proportionally with fat mass, but leptin resistance may blunt its satiety effect. The net caloric intake change varies widely between individuals.

What remains consistent is the mismatch between intake and expenditure. Even without increased eating, the reduced BMR and thermogenesis create positive energy balance. When appetite does rise — whether from hypothalamic dysregulation or compensatory mechanisms — weight gain accelerates. This variability explains why some patients gain substantial weight while others remain stable despite similar thyroid function.

Insulin Sensitivity, Glucose Disposal, and Fat Partitioning

Hypothyroidism impairs insulin signaling in liver, muscle, and adipose tissue. Reduced thyroid hormone action decreases GLUT4 translocation in skeletal muscle and adipocytes, blunting glucose uptake. Hepatic insulin resistance develops, increasing gluconeogenesis and fasting glucose. Compensatory hyperinsulinemia follows, which promotes lipogenesis and inhibits hormone-sensitive lipase, further favoring fat storage.

The combination of hyperinsulinemia and reduced lipid oxidation shifts substrate partitioning toward carbohydrate utilization at rest and fat storage postprandially. Visceral adipose tissue, which is more metabolically active and insulin-sensitive than subcutaneous fat, expands preferentially. This visceral adiposity worsens systemic insulin resistance, creating a feed-forward loop that amplifies weight gain and metabolic risk.

Thyroid replacement improves insulin sensitivity, but the timeline varies. Muscle glucose disposal normalizes within weeks, while hepatic insulin resistance and visceral fat reduction may take months. Patients with preexisting insulin resistance or metabolic syndrome may experience more persistent weight difficulty even after biochemical euthyroidism is achieved.

Metabolic Parameter	Euthyroid State	Hypothyroid State	Effect on Weight
Basal metabolic rate	Normal	Decreased 15–30%	Reduces daily energy expenditure
Lipolysis	T3-stimulated	Suppressed	Decreases fat mobilization
Lipoprotein lipase activity	Baseline	Increased	Enhances fatty acid uptake into adipocytes
LDL receptor expression	Normal	Decreased	Raises serum LDL, alters lipid flux
Brown adipose thermogenesis	Active UCP1	Suppressed UCP1	Reduces energy dissipation as heat
Insulin sensitivity	Normal	Impaired	Promotes lipogenesis and fat storage
Glycosaminoglycan turnover	Normal degradation	Reduced degradation	Causes fluid retention (myxedema)

Muscle Metabolism, Physical Activity, and Energy Expenditure

Skeletal muscle expresses high levels of thyroid hormone receptors and is a major determinant of total energy expenditure. Hypothyroidism induces a slow-twitch fiber shift, reduces mitochondrial density, and decreases activity of oxidative enzymes (citrate synthase, cytochrome c oxidase). Muscle contractility weakens, and exercise tolerance declines, leading to reduced spontaneous physical activity and lower non-exercise activity thermogenesis (NEAT).

Myopathy affects 30 to 80 percent of overtly hypothyroid patients, manifesting as proximal weakness, cramps, and elevated creatine kinase. This functional limitation creates a behavioral feedback loop: patients move less because of fatigue and discomfort, further lowering total daily energy expenditure beyond the BMR reduction. NEAT can vary by hundreds of calories daily, making it a potent modulator of weight trajectory.

Thyroid hormone replacement reverses muscle biochemical abnormalities within 4 to 8 weeks, but functional recovery of strength and endurance often lags. Structured resistance training during this period can accelerate mitochondrial biogenesis and fiber-type normalization, helping restore the activity-related energy expenditure that protects against weight regain.

Hormonal Interactions Beyond Thyroid Axis

Hypothyroidism disrupts multiple endocrine axes that secondarily influence weight. Growth hormone (GH) secretion becomes blunted, reducing lipolytic drive and lean mass maintenance. Cortisol clearance slows due to reduced 5-alpha-reductase activity, causing mild functional hypercortisolism that promotes visceral adiposity and insulin resistance. Sex hormone-binding globulin (SHBG) decreases, altering free estrogen and testosterone ratios in ways that may favor fat deposition.

Prolactin often rises in primary hypothyroidism due to TRH-mediated pituitary stimulation. Hyperprolactinemia can suppress gonadotropins, contributing to hypogonadism and its associated metabolic effects. In men, low testosterone reduces muscle mass and increases fat mass; in women, estrogen-progesterone imbalance may affect fat distribution and appetite regulation.

These hormonal perturbations are largely reversible with thyroid normalization, but their combined effect during the hypothyroid state creates a multilayered metabolic environment that resists weight loss. Understanding this network explains why simply restricting calories often fails in untreated hypothyroidism — the endocrine milieu actively partitions energy toward storage regardless of intake.